New hope for advanced liver cancer: experimental drug takes on standard therapy
NCT ID NCT07300488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new drug, pracytarabine, to the standard drug regorafenib in 60 people with advanced liver cancer that has stopped responding to targeted therapy and immunotherapy. The goal is to see if pracytarabine can help patients live longer. Participants receive either drug by infusion or pill, and researchers track survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pracytarabine
What this could lead to
If it works, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong
This is an early-to-mid-stage trial with only 60 participants, so results may not apply widely. The new drug may not work better or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, 211100, China